Reported adverse events in intervention and comparator groups among participants in statin primary prevention randomised controlled trials, updated to include HOPE-3 trial data published in 201611
| Statin | Usual care or placebo | |||||
|---|---|---|---|---|---|---|
| Study ID | Events | Total | Events | Total | Weight (%) | Risk ratio (fixed effect) |
| Adult Japanese MEGA Study 2006 | 451 | 3866 | 397 | 3966 | 5.7 | 1.17 (1.03 to 1.32) |
| AFCAPS/TexCAPS 1998 | 1045 | 3304 | 1126 | 3301 | 16.3 | 0.93 (0.87 to 0.99) |
| ASPEN 2006 | 361 | 959 | 334 | 946 | 4.9 | 1.07 (0.95 to 1.20) |
| Bone 2007 | 413 | 485 | 102 | 119 | 2.4 | 0.99 (0.92 to 1.08) |
| CAIUS 1996 | 21 | 151 | 21 | 154 | 0.3 | 1.02 (0.58 to 1.79) |
| CARDS 2008 | 1390 | 1428 | 1376 | 1410 | 20.1 | 1.00 (0.99 to 1.01) |
| Derosa 2003 | 0 | 24 | 0 | 23 | Not estimable | |
| HOPE-3 2016 | 1643 | 6361 | 1633 | 6344 | 23.7 | 1.00 (0.95 to 1.06) |
| JUPITER 2008 | 1352 | 8901 | 1377 | 8901 | 20.0 | 0.98 (0.92 to 1.05) |
| KAPS 1995 | 107 | 214 | 95 | 212 | 1.4 | 1.12 (0.91 to 1.36) |
| METEOR 2010 | 583 | 700 | 226 | 281 | 4.7 | 1.04 (0.97 to 1.11) |
| PHYLLIS 2004 | 12 | 253 | 14 | 254 | 0.2 | 0.86 (0.41 to 1.82) |
| PREVEND IT 2004 | 13 | 433 | 22 | 431 | 0.3 | 0.59 (0.30 to 1.15) |
| Total (95% CI) | 27 079 | 26 342 | 100.0 | 1.00 (0.97 to 1.02) | ||
| Total events | 7391 | 6723 | ||||
Heterogeneity: χ2=16.43, df=11.
(p=0.13); I2=33%.